Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 May:104:106355.
doi: 10.1016/j.cct.2021.106355. Epub 2021 Mar 10.

Central monitoring in a randomized, open-label, controlled phase 3 clinical trial for a treatment-shortening regimen for pulmonary tuberculosis

Kia E Bryant  1 , Yan Yuan  2 , Melissa Engle  3 , Ekaterina V Kurbatova  2 , Cynthia Allen-Blige  4 , Kumar Batra  4 , Nicole E Brown  2 , Kuo Wei Chiu  4 , Howard Davis  4 , Mascha Elskamp  5 , Melissa Fagley  2 , Pamela Fedrick  4 , Kimberley N C Hedges  6 , Kim Narunsky  7 , Joanita Nassali  8 , Mimi Phan  9 , Ha Phan  10 , Anne E Purfield  11 , Jessica N Ricaldi  2 , Kathleen Robergeau-Hunt  12 , William C Whitworth  2 , Erin E Sizemore  2 ; AIDS Clinical Trials Group; Tuberculosis Trials Consortium
Affiliations
Clinical Trial

Central monitoring in a randomized, open-label, controlled phase 3 clinical trial for a treatment-shortening regimen for pulmonary tuberculosis

Kia E Bryant et al. Contemp Clin Trials. 2021 May.

Abstract

Introduction: With the growing use of online study management systems and rapid availability of data, timely data review and quality assessments are necessary to ensure proper clinical trial implementation. In this report we describe central monitoring used to ensure protocol compliance and accurate data reporting, implemented during a large phase 3 clinical trial.

Material and methods: The Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) study A5349 (S31) is an international, multi-site, randomized, open-label, controlled, non-inferiority phase 3 clinical trial comparing two 4-month regimens to a standard 6 month regimen for treatment of drug-susceptible tuberculosis (TB) among adolescents and adults with a sample size of 2500 participants.

Results: Central monitoring utilized primary study data in a five-tiered approach, including (1) real-time data checks & topic-specific intervention reports, (2) missing forms reports, (3) quality assurance metrics, (4) critical data reports and (5) protocol deviation identification, aimed to detect and resolve quality challenges. Over the course of the study, 240 data checks and reports were programed across the five tiers used.

Discussion: This use of primary study data to identify issues rapidly allowed the study sponsor to focus quality assurance and data cleaning activities on prioritized data, related to protocol compliance and accurate reporting of study results. Our approach enabled us to become more efficient and effective as we informed sites about deviations, resolved missing or inconsistent data, provided targeted guidance, and gained a deeper understanding of challenges experienced at clinical trial sites.

Trial registration: This trial was registered with ClinicalTrials.gov (Identifier: NCT02410772) on April 8, 2015.

Keywords: Central monitoring; Clinical trial; Clinical trial quality assurance; Tuberculosis.

PubMed Disclaimer

Conflict of interest statement

Competing interests

The authorship team members have declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Sanofi commercial interests did not influence the study design; the collection, analysis, or interpretation of data; the preparation of this manuscript; or the decision to submit this manuscript for publication. A Sanofi technical expert served on the protocol team.

Figures

Figure 1.
Figure 1.
Quality Monitoring Map for Study TBTC S31 / ACTG A5349
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Humane Use, “FDA Guidance Documents,” 8 May 2019. [Online]. Available: https://www.fda.gov/media/129527/download.
    1. Ghone A, “Applied Clinical Trials,” 01 October 2015. [Online]. Available: http://www.appliedclinicaltrialsonline.com/centralized-monitoring-smart-....
    1. US Food & Drug Administration, “Guidance for Industry: Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring,” August 2013. [Online]. Available: https://www.fda.gov/media/116754/download.
    1. Venet D, Doffagne E, Burzykowski T, Beckers F, Tellier Y, Genevois-Marlin E, Becker U, Bee V, Wilson V, Legrand C and Buyse M, “A statistical approach to central monitoring of data quality in clinical trials,” Clinical Trials, vol. 9, pp. 705–713, 2012. - PubMed
    1. Agrafiotis D, Lobanov VS, Farnum MA, Yang E, Ciervo J, Walega M, Baumgart A and Mackey AJ, “Risk-based Monitoring of Clinical Trials: An Integrative Approach,” Clinical Therapeutics, vol.40, no. 7, pp. 1204–1212, 2018. - PubMed

Publication types

Substances

Associated data